CONTRAFECT CORP (CFRX) Stock Price, Quote, News and Overview
NASDAQ:CFRX - Nasdaq - US2123264093 - Common Stock - Currency: USD
CFRX Quote, Performance and Key Statistics
0.2318
+0.01 (+2.84%)
The current stock price of CFRX is 0.2318 USD. In the past month the price decreased by -52.79%. In the past year, price decreased by -97.99%.
CFRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CFRX
Company Profile
ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. The company is headquartered in Yonkers, New York and currently employs 23 full-time employees. The company went IPO on 2014-07-29. The firm is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.
Company Info
CONTRAFECT CORP
28 Wells Avenue, 3rd Floor
Yonkers NEW YORK 10701 US
CEO: Roger J. Pomerantz
Employees: 23
Company Website: https://www.contrafect.com/
Phone: 19142072300.0
CONTRAFECT CORP / CFRX FAQ
What is the stock price of CONTRAFECT CORP today?
The current stock price of CFRX is 0.2318 USD. The price increased by 2.84% in the last trading session.
What is the ticker symbol for CONTRAFECT CORP stock?
The exchange symbol of CONTRAFECT CORP is CFRX and it is listed on the Nasdaq exchange.
On which exchange is CFRX stock listed?
CFRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CONTRAFECT CORP stock?
7 analysts have analysed CFRX and the average price target is 5.1 USD. This implies a price increase of 2100.17% is expected in the next year compared to the current price of 0.2318. Check the CONTRAFECT CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CONTRAFECT CORP worth?
CONTRAFECT CORP (CFRX) has a market capitalization of 1.27M USD. This makes CFRX a Nano Cap stock.
How many employees does CONTRAFECT CORP have?
CONTRAFECT CORP (CFRX) currently has 23 employees.
What are the support and resistance levels for CONTRAFECT CORP (CFRX) stock?
CONTRAFECT CORP (CFRX) has a resistance level at 0.26. Check the full technical report for a detailed analysis of CFRX support and resistance levels.
Should I buy CONTRAFECT CORP (CFRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CFRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CFRX, evaluating the profitability, health, valuation and growth aspects
- CONTRAFECT CORP (CFRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CONTRAFECT CORP (CFRX) Sales and EPS estimates to see what analysts future expectations are.
- CONTRAFECT CORP (CFRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CONTRAFECT CORP (CFRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- CONTRAFECT CORP (CFRX) Stock Chart to make your own analysis
- CONTRAFECT CORP (CFRX) Latest news and press-releases to stay up to date.
Does CONTRAFECT CORP (CFRX) stock pay dividends?
CFRX does not pay a dividend.
When does CONTRAFECT CORP (CFRX) report earnings?
CONTRAFECT CORP (CFRX) will report earnings on 2024-03-29, after the market close.
What is the Price/Earnings (PE) ratio of CONTRAFECT CORP (CFRX)?
CONTRAFECT CORP (CFRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-37.17).
CFRX Technical Analysis
CFRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CFRX. CFRX may be in some trouble as it scores bad on both profitability and health.
CFRX Financial Highlights
Over the last trailing twelve months CFRX reported a non-GAAP Earnings per Share(EPS) of -37.17. The EPS increased by 61.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -186.23% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CFRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CFRX. The Buy consensus is the average rating of analysts ratings from 7 analysts.